Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
A better understanding of the roles of the adaptive and innate immune systems in the
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma
Infections are the most common complication of treatment with novel immunotherapies and
the second most common cause of death in multiple myeloma after the disease itself. 1 …
the second most common cause of death in multiple myeloma after the disease itself. 1 …
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
R Chakraborty, H Cheruvalath, A Patwari… - Blood Cancer …, 2024 - nature.com
Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-
coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and …
coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and …
Bispecific antibodies for the management of relapsed/refractory multiple myeloma
Simple Summary Bispecific antibodies (BsAbs) provide a new mode of targeting multiple
myeloma (MM) plasma cells (PCs), basing their action on the activation and redirection of …
myeloma (MM) plasma cells (PCs), basing their action on the activation and redirection of …
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the …
CC Mo, E Richardson, E Calabretta, F Corrado… - Blood Reviews, 2024 - Elsevier
Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
RD Parrondo, S Ailawadhi, C Cerchione - Frontiers in Oncology, 2024 - frontiersin.org
Patients with relapsed/refractory multiple myeloma (RRMM) that are refractory to the five
most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal …
most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal …
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …
Mitigating time toxicity in lymphoma and multiple myeloma
The concept of time toxicity in oncology refers to the presence of frequent healthcare-related
interactions that can interfere with patient well-being. In this review, we examine several …
interactions that can interfere with patient well-being. In this review, we examine several …